Biota Pharmaceuticals Inc  

(Public, NASDAQ:BOTA)   Watch this stock  
Find more results for BOTA
2.40
-0.04 (-1.64%)
Oct 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.37 - 2.42
52 week 2.10 - 7.07
Open 2.42
Vol / Avg. 0.00/49,010.00
Mkt cap 85.65M
P/E     -
Div/yield     -
EPS -0.34
Shares 35.10M
Beta 1.14
Inst. own 48%
Nov 11, 2014
Biota Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EST - Add to calendar
Nov 7, 2014
Q1 2015 Biota Pharmaceuticals Inc Earnings Release - 9:30AM EST - Add to calendar
Nov 7, 2014
Q1 2015 Biota Pharmaceuticals Inc Earnings Call - 9:00AM EST - Add to calendar
Sep 26, 2014
Q4 2014 Biota Pharmaceuticals Inc Earnings Release
Sep 26, 2014
Q4 2014 Biota Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -121.43% -16.01%
Operating margin -125.00% -16.74%
EBITD margin - -11.21%
Return on average assets -34.89% -11.01%
Return on average equity -44.74% -14.20%
Employees 66 -
CDP Score - -

Address

2500 Northwinds Pkwy Ste 100
ALPHARETTA, GA 30009-2248
United States - Map
+1-678-2213343 (Phone)
+1-301-7703097 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�s researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan. The Company�s products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI).

Officers and directors

Peter J. Azzarello CPA Chief Accounting Officer, Vice President - Finance
Age: 43
Bio & Compensation  - Reuters
Russell H. Plumb Executive Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Joseph M. Patti Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
James Charles Fox Ph.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 56
Bio & Compensation  - Reuters
John P. Richard Independent Director
Age: 57
Bio & Compensation  - Reuters
Anne M. VanLent Independent Director
Age: 66
Bio & Compensation  - Reuters